Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review

Journal of Infection

Volumn 62, Issue 1, 2011, Pages 14-25

  Jackson, Rachel J ^a   Cooper, Katy L ^a   Tappenden, Paul ^a   Rees, Angie ^a   Simpson, Emma L ^a   Read, Robert C ^b   Nicholson, Karl G ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Amantadine; Influenza; M2 inhibitor; Neuraminidase inhibitor; Oseltamivir; Prevention; Prophylaxis; Systematic review; Zanamivir

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; PLACEBO; ZANAMIVIR;

ARTICLE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ENVIRONMENTAL EXPOSURE; EPIDEMIC; GASTROINTESTINAL TOXICITY; HOUSEHOLD; HUMAN; INFECTION CONTROL; INFECTION RISK; INFLUENZA B; LABORATORY TEST; SEASONAL INFLUENZA; SLEEP DISORDER; SYMPTOM; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE; VOMITING;

AMANTADINE; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; POST-EXPOSURE PROPHYLAXIS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS; ZANAMIVIR;

EID: 78751614259     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.10.003     Document Type: Article

References (85)

1. Douglas R.G. Prophylaxis and treatment of influenza. N Engl J Med 1990, 322:443-450.
2. Health Protection Agency. 18-12-2007.
3. Nicholson K.G. Human influenza. Textbook of influenza 1998, Blackwell Science, Oxford. K.G. Nicholson, R.G. Webster, A.J. Hay (Eds.).
4. Tillett H.E., Smith J.W.G., Gooch C.D. Excess deaths attributable to influenza in England and Wales: age at death and certified cause. Int J Epidemiol 1983, 12:344-352.
5. Nicholson K.G. Impact of influenza and respiratory syncitial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect 2009, 116:51-63.
6. Fleming D.M. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health 2000, 3:32-38.
7. National Institute for Health and Clinical Excellence. Oseltamivir and amantadine for the prophylaxis of influenza. Technology Appraisal Guidance 67, 2003.
8. National Institute for Clinical Excellence. Oseltamivir, amatadine (review) and zanamivir for the prophylaxis of influenza. Technology Appraisal Guidance 158, 2008.
9. Tappenden P., Jackson R., Cooper K., Rees A., Simpson E., Read R., et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009 Feb, 13(11):246. iii, ix-iii.
10. British National Formulary. 2007.
11. NHS Centre for Reviews and Dissemination. Report 4: Undertaking systematic reviews on effectiveness; CRDs guidance for those carrying out or commissioning reviews. 2001.
12. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:332-336. for the PRISMA Group.
13. Hess P. Amantadine and rimantadine in the prophylaxis of influenza A. Med Hyg 1982, 40(1487):3496.
14. Plesnik V., Heinz F., Bindas B., Cechova D., Eliasova J., Galetkova A., et al. Controlled study of influenza prophylaxis by VUFB amantadin. Cesk Epidemiol Mikrobiol Imunol 1977, 26(4):216-226.
15. Quilligan J.J., Hirayama M., Baernstein H.D. The prevention of A2-influenza in children by chemoprophylaxis with amantadine hydrochloride. Schweiz Med Wochenschr 1966 Dec 17, 96(50):1689-1692. Journal Suisse de Medecine.
16. Smorodintsev A.A., Zlydnikov D.M., Romanov I., Rumovski V.I., Smorodintsev A.A., Zlydnikov D.M., et al. Effectiveness of amantadine hydrochloride (midantane) in prevention of artificially induced influenza. Vopr Virusol 1972 Mar, 17(2):152-156.
17. Kashiwagi S., Kudoh S., Watanabe A., Yoshimura I. Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza-placebo-controlled double-blind multicenter phase III trial. Kansenshogaku Zasshi 2000, 74(12):1062-1076.
18. Shinjoh M., Sato S., Sugaya N., Mitamura K., Takeuchi Y., Kosaki K., et al. Effect of post-exposure prophylaxis with oseltamivir for those in contacts with influenza patients in pediatric wards. Kansenshogaku Zasshi 2004, 78(3):262-269.
19. Diaz-Pedroche C., Lizasoain M., Lopez-Medrano F., Escalante F., Lumbreras C., Folgueira D., et al. Nosocomial outbreak of influenza in high-risk hematological patients. Efficacy of control measures and the use of zanamivir. Enferm Infecc Microbiol Clin 2006 Jan, 24(1):10-13.
20. Aoki F.Y., Stiver H.G., Sitar D.S., Boudreault A., Ogilvie R.I., Aoki F.Y., et al. Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults. Clin Pharmacol Ther 1985 Feb, 37(2):128-136.
21. Bryson Y.J., Monahan C., Pollack M., Shields W.D. A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J Infect Dis 1980, 141(5):543-547.
22. Callmander E., Hellgren L. Amantadine hydrochloride as a prophylactic in respiratory infections. A double-blind investigation of its clinical use and serology. J Clin Pharmacol J New Drugs 1968, 8(3):186-189.
23. Cohen A., Togo Y., Khakoo R., Waldman R., Sigel M. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis 1976, 133(Suppl:A114-A120).
24. Dawkins A.T., Gallager L.R., Togo Y., Hornick R.B., Harris B.A. Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. JAMA 1968, 203(13):1095-1099.
25. Dolin R., Reichman R.C., Madore H.P., Maynard R., Linton P.N., Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982, 307(10):580-584.
26. Finklea J.F., Hennessy A.V., Davenport F.M. A field trial of amantadine prophylaxis in naturally-occurring acute respiratory illness. Am J Epidemiol 1967, 85(3):403-412.
27. Galbraith A.W., Oxford J.S., Schild G.C., Watson G.I. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study. Lancet 1969, 2(7629):1026-1028.
28. Galbraith A.W., Oxford J.S., Schild G.C., Watson G.I. Study of 1-adamantanamine hydrochloride used prophylactically during the Hong Kong influenza epidemic in the family environment. Bull World Health Organ 1969, 41(3):677-682.
29. Galbraith A.W., Oxford J.S., Schild G.C., Potter C.W., Watson G.I. Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A2-Hong Kong infection. A controlled double-blind study. Lancet 1971, 2(7716):113-115.
30. Hayden F., Gwaltney J.M., Van de Castle R.L., Adams K.F., Giordani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 1981, 19(2):226-233.
31. Jackson G.G., Muldoon R.L., Akers L.W. Serological evidence for prevention of influenzal infection in volunteers by an anti-influenzal drug adamantanamine hydrochloride. Antimicrob Agents Chemother 1963, 161:703-707.
32. Kantor R.J., Stevens D., Potts D.W., Noble G.R. Prevention of influenza A/USSR/77 (H1N1): an evaluation of the side effects and efficacy of amantadine in recruits at Fort Sam Houston. Mil Med 1980, 145(5):312-315.
33. Leeming J.T. Amantidine hydrochloride and the elderly. BMJ 1969, 1(5639):313-314.
34. Leung P., McIntosh K., Chai H. Amantadine prophylaxis against influenza A/USSR in children with chronic asthma. J Allergy Clin Immunol 1979, 63(3):140.
35. Máté J., Simon M., Juvancz I., Takátsy G., Hollós I., Farkas E. Prophylactic use of amantadine during Hong Kong influenza epidemic. Acta Microbiol Acad Sci Hung 1970, 17(3):285-296.
36. Millet V.M., Dreisbach M., Bryson Y.J. Double-blind controlled study of central nervous system side effects of amantadine, rimantadine and chlorpheniramine. Antimicrob Agents Chemother 1982, 21(1):1-4.
37. Monto A.S., Gunn R.A., Bandyk M.G., King C.L. Prevention of Russian influenza by amantadine. JAMA 1979, 241(10):1003-1007.
38. Muldoon R.L., Stanley E.D., Jackson G.G. Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A. Am Rev Respir Dis 1976, 113(4):487-491.
39. Nafta I., TTurcanu A.G., Braun I., Companetz W., Simionescu A., Birt E., et al. Administration of amantadine for the prevention of Hong Kong influenza. Bull World Health Organ 1970, 42(3):423-427.
40. O'Donoghue J.M., Ray C.G., Terry D.W., Beaty H.N. Prevention of Nosocomial influenza infection with amantadine. Am J Epidemiol 1973, 97(4):276-282.
41. Oker-Blom N., Hovi T., Leinikki P., Palosuo T., Pettersson R., Suni J. Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled field trial. BMJ 1970, 3(5724):676-678.
42. Peckinpaugh R.O., Askin F.B., Pierce W.E., Edwards E.A., Johnson D.P., Jackson G.G. Field studies with amantadine: acceptability and protection. Ann N Y Acad Sci 1970, 173:62-73.
43. Quarles J.M., Couch R.B., Cate T.R., Goswick C.B. Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza. Antiviral Res 1981, 1(3):149-155.
44. Quilligan J.J., Hirayama M., Baernstein H.D. The suppression of A2 influenza in children by the chemoprophylactic use of Amantadine. J Pediatr 1966, 69(4):572-575.
45. Schapira M., Oxford J., Galbraith W. A study of adamantamine hydrochloride during the 1970 Hong Kong influenza epidemic. J R Coll Gen Pract 1971, 21:695-697.
46. Stanley E.D., Muldoon R.E., Akers L.W., Jackson G.G. Evaluation of antiviral drugs: the effect of amantadine on influenza in volunteers. Ann N Y Acad Sci 1965, 130:44-51.
47. Togo Y., Hornick R.B., Dawkins A.T. Studies on induced influenza in man. I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain. JAMA 1968, 203(13):1089-1094.
48. Tyrell D.A.J., Bynoe M.L., Dawkins A.T. Studies on the antiviral activity of 1-adamantanamine. Br J Exp Pathol 1965, 46(370):375.
49. Wendel H.A., Snyder M.T., Pell S. Trial of amantadine in epidemic influenza. Clin Pharmacol Ther 1966, 7(1):38-43.
50. Wright P.F., Khaw K.T., Oxman M.N., Shwachma H. Amantadine for prophylaxis of influenza in patients with cystic-fibrosis. Pediatr Res 1974, 8(4):430.
51. Wright P.F., Khaw K.T., Oxman M.N., Shwachman H. Evaluation of the safety of amantadine-HC1 and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis 1976, 134(2):144-149.
52. Calfee D.P., Peng A.W., Hussey E.K., Lobo M., Hayden F.G. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antivir Ther 1999, 4(3):143-149.
53. Calfee D.P., Peng A.W., Cass L.M., Lobo M., Hayden F.G. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999, 43(7):1616-1620.
54. Cass L.M.R., Gunawardena K.A., MacMahon M.M., Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med 2000, 94(2):166-173.
55. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996, 275(4):295-299.
56. Schilling M., Povinelli L., Krause P., Gravenstein M., Ambrozaitis A., Jones H., et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine 1998, 16(18):1771-1774.
57. Walker J.B., Hussey E.K., Treanor J.J., Montalvo A., Hayden F.G. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis 1997, 176(6):1417-1422.
58. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999, 282(13):1240-1246.
59. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA;285(6):748-754.
60. Hayden F.G., Belshe R., Villanueva C., Lanno R., Hughes C., Small I., et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004, 189(3):440-449.
61. Peters P.H., Gravenstein S., Norwood P., De Bock V., Van Couter A., Gibbens M., et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001, 49(8):1025-1031.
62. Hayden F.G., Atmar R.L., Schilling M., Johnson C., Poretz D., Paar D., et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999, 341(18):1336-1343.
63. Monto A.S., Pichichero M.E., Blanckenberg S.J., Ruuskanen O., Cooper C., Fleming D.M., et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002, 186(11):1582-1588.
64. Hayden F.G., Gubareva L.V., Monto A.S., Klein T.C., Elliott M.J., Hammond J.M., et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000, 343(18):1282-1289.
65. Kaiser L., Henry D., Flack N.P., Keene O., Hayden F.G. Short-term treatment with zanamivir to prevent influenza: Results of a placebo-controlled study. Clin Infect Dis 2000, 30(3):587-589.
66. Ambrozaitis A., Gravenstein S., Van Essen G.A., Rubinstein E., Balciuniene L., Stikleryte A., et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc 2005, 6(6):367-374.
67. Payler D.K., Purdham P.A. Influenza A prophylaxis with amantadine in a boarding school. Lancet 1984, 1(8375):502-504.
68. Smorodintsev A., Karpuchin G., Zlydnikov D. The prospect of amantadine for prevention of influenza A in humans (effectiveness of amantadine during influenza A2/Hong Kong epidemics in January-February 1969 in Leningrad. Ann N Y Acad Sci 1970, 173:44-73.
69. Smorodintsev A.A., Karapuhi G.I., Zlydniko D.M., Malyseva A.M., Svecova E.G., Burov S.A., et al. Prophylactic effectiveness of amantadine hydrochloride in an epidemic of Hong-Kong influenza in Leningrad in 1969. Bull World Health Organ 1970, 42(6):865-872.
70. Reuman P.D., Bernstein D.I., Keefer M.C., Young E.C., Sherwood J.R., Schiff G.M. Efficacy and safety of low dosage amantadine hydrochloride As prophylaxis for influenza A. Antiviral Res 1989, 11(1):27-40.
71. Aoki F.Y., Stiver H.G., Sitar D.S., Hammond G.W., Milley E.V., Vermeersch C., et al. Potential of influenza vaccine and amantadine to prevent influenza A illness in Canadian forces personnel 1980-1983. Mil Med 1986 Sep, 151(9):459-465.
72. Monto A.S., Robinson D.P., Louise M., James H., Hinson M., Elliott M.J., et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999, 282(1):31-35.
73. LaForce C., Man C.Y., Henderson F.W., McElhaney J.E., Hampel F.C., Bettis R., et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2007, 29(8):1579-1590.
74. Gravenstein S., Drinka P., Osterweil D., Schilling M., Krause P., Elliott M., et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc 2005, 6(6):359-366.
75. Pettersson R.F., Hellström P.E., Penttinen K., Pyhälä R., Tokola O., Vartio T., et al. Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients. J Infect Dis 1980, 142(3):377-383.
76. Monto A.S., Robinson D., Griffin A.D., Edmundson S. The effects of zanamivir on productivity in the prevention of influenza among healthy adults. J Antimicrob Chemother 1999, 44(Suppl. A).
77. Cooper N.J., Sutton A.J., Abrams K.R., Wailoo A., Turner D.A., Nicholson K.G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003, 326(7401):1235-1239.
78. Shun-Shin M., Thompson M., Heneghan C., Perera R., Harnden A., Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 2009, 339:b3172.
79. Jefferson T., Jones M., Doshi P., Del M.C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009, 339:b5106.
80. Health Protection Agency. HPA weekly national influenza report. 15-4-2009.
81. World Health Organisation. Weekly update on oseltamivir resistance to pandemic influenza A (H1N1) 2009 viruses. 2010 Jul 7.
82. De Bock V., Peters P., Von Planta T.-A., Gibbens M., Ward P. Oral oseltamivir for prevention of influenza in the frail elderly. Clin Microbiol Infect 2000, 6(Suppl. 1):140.
83. Hayden F., Belshe R., Villanueva C., Lanno R., Small I., Hughes C., et al. Oral oseltamivir prevents the spread of influenza between children in households. Abstr Intersci Conf Antimicrob Agents Chemother 2002, 42.
84. Belshe R., Hayden F., Carewicz O., Lanno R., Martin C., Hughes C., et al. Effectiveness of oral oseltamivir in preventing spread of influenza-like illness in households with proven influenza. Abstr Intersci Conf Antimicrob Agents Chemother 2001, 41.
85. Ambrozaitis A., VanEssen G., Rubinstein E., Balciuiene L., Stikleryte A., Gravenstein S., et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population (NAIA3004). J Am Geriatr Soc 2001, 49(4):S130-S131.